Zolbetuximab
Yes
Yes
No
Active ingredient: Zolbetuximab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended zolbetuximab, in combination with chemotherapy, for inclusion on the MOH List of Subsidised Drugs for untreated HER2-negative, claudin-18.2-positive, unresectable advanced gastric or gastroesophageal junction adenocarcinoma. The decision was based on the unfavourable cost effectiveness of zolbetuximab plus chemotherapy compared with alternative treatments, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for zolbetuximab plus chemotherapy are provided in the Annex.
